Lyra Therapeutics, Inc. - LYRA STOCK NEWS

Lyra Therapeutics, Inc. (Nasdaq: LYRA) reported Q1 2021 financial results, highlighting the positive full data set from its LANTERN Phase 2 Study of LYR-210 for chronic rhinosinusitis, presented at COSM 2021. The study showed effectiveness in non-polyp and polyp patients, with 100% achieving SNOT-22 MCID at week 24. The company has $66.1 million in cash, down from $74.6 million, with R&D expenses rising to $4.8 million. A Phase 3 trial for LYR-210 is planned by year-end, pending FDA approval. Lyra expects sufficient cash to fund operations into 2023.

Lyra Therapeutics (Nasdaq: LYRA) announced that CEO Maria Palasis, Ph.D., will present at the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021, at 4:15 p.m. ET. The presentation can be accessed via the company's website, with a replay available for 30 days afterward. Lyra is focused on developing innovative drug delivery solutions for ENT diseases, notably its lead candidate LYR-210 for chronic rhinosinusitis. The company believes its XTreo™ platform may extend its applications beyond ENT treatments.

Lyra Therapeutics, Inc. (Nasdaq: LYRA) will announce its Q1 2021 financial results on May 11, 2021, after market close and host a conference call at 4:30 p.m. ET. Lyra focuses on developing integrated drug delivery solutions for ENT diseases, notably its lead product candidate LYR-210, designed for chronic rhinosinusitis treatment. The press release emphasizes the company's ongoing clinical trials and innovation in drug delivery using its XTreo™ platform, which aims to provide sustained medication release.

Lyra Therapeutics (Nasdaq: LYRA) presented data from its Phase 2 LANTERN study of LYR-210, targeting chronic rhinosinusitis (CRS), at the Combined Otolaryngology Spring Meetings 2021. LYR-210 is a long-acting, non-invasive alternative for patients who failed medical management. The study showed significant improvement in both polyp and non-polyp patients, with 100% achieving minimal clinically important difference in symptoms. Key findings included a reduction in rescue medication use and improved imaging results. The data supports further development towards a pivotal Phase 3 trial.

Lyra Therapeutics, Inc. (Nasdaq: LYRA) announced that it will present Phase 2 results from the LANTERN study for LYR-210 at the Combined Otolaryngology Spring Meetings (COSM) 2021, occurring from April 7-11, 2021. The oral presentation is scheduled for April 11 at 2:36 p.m. CT, featuring data on LYR-210, which aims to provide up to six months of corticosteroid therapy for chronic rhinosinusitis. This study is a significant step for Lyra as it seeks to enhance treatment protocols for patients with ENT diseases.

Lyra Therapeutics, Inc. (NASDAQ: LYRA) reported positive financial results for Q4 and FY 2020, highlighting the success of the LANTERN Phase 2 study for LYR-210, which shows promise for Chronic Rhinosinusitis treatment. The drug demonstrated significant improvements in symptom scores and extended benefits post-administration. Despite a net loss of $7 million for Q4 and $22.1 million for the year, Lyra ended the year with $74.6 million in cash, sufficient to fund operations into 2023. Key appointments, including Dr. Robert Kern as Chief Medical Officer, strengthen the team as the company plans pivotal trials.

Lyra Therapeutics, Inc. (Nasdaq: LYRA) will release its fourth quarter and full year 2020 financial results on March 9, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and corporate updates. Lyra focuses on innovative drug delivery solutions for ENT diseases, with lead candidate LYR-210 targeting chronic rhinosinusitis. The company emphasizes that it has incurred significant losses since inception and may require additional funding, which may not be available.

Lyra Therapeutics, Inc. (Nasdaq: LYRA) has appointed Robert Kern, MD, as Chief Medical Officer, while he continues his role at Northwestern University. Dr. Kern is an expert in chronic rhinosinusitis (CRS) and has over 30 years of experience in ENT. His leadership is expected to enhance the company’s clinical pipeline, especially for its product candidates LYR-210 and LYR-220, which have shown positive Phase 2 results. The company aims to address significant treatment needs in CRS.

Lyra Therapeutics (Nasdaq: LYRA) announced significant updates regarding its lead product candidate, LYR-210, in a recent corporate update for 2021. The LANTERN Phase 2 study demonstrated positive topline results, showcasing significant improvement in chronic rhinosinusitis (CRS) symptoms. Lyra plans to discuss these findings with the FDA and intends to initiate a pivotal Phase 3 trial by late 2021. Cash and equivalents stood at $74.6 million as of December 31, 2020, sufficient to fund operations into 2023, exceeding prior guidance.